KANJINTI 150 mg prašek za koncentrat za raztopino za infundiranje
Trastuzumab
General information
Drug nameKANJINTI 150 mg prašek za koncentrat za raztopino za infundiranje
Medicine nameTrastuzumab
National drug code3000037
PMS ID—
SNOMED descriptive name code—
Legal statusZdravilo z dovoljenjem za promet
Drug groupSimilar Biological Medicinal Product
OriginatorNo
Orphan drugNo
Marketing authorization
Procedure typePotrditev podatkov za CP zdravila (modro okence)
No. and date of decision/certificate1024-47/2018-3, 29. 5. 2018
Authorization validity dateUntil further notice
Marketing end date—
Application type—
Authorization/certificate holderAmgen Europe B.V.
Drug safety monitoring
Additional safety monitoringNo
Precautionary measure/dispensing restrictions—
Pregnancy prevention programmeNo
Controlled access programme(s)No
ATC codes
Route of administration
Route of administration name
Intravenska uporaba
Settlement data for compulsory health insurance billing
Substitute medicine
Preparation—
Valid from – to—
Clinical use data
Methods of use—
Indications—
Rounding factor—
DivisibleNo
Division for easier swallowingNo
Division for dosage adjustmentNo
Paediatric populationNo
Shortage actions
Substitute medicine in case of shortage - industrial medicine—
Substitute medicine in case of shortage - magistral or galenic medicine—
Prescribing restriction in case of drug shortageNo
Dispensing restriction in case of shortage or emergencyNo
Dispensing restriction for foreign prescriptions in case of shortage or emergencyNo
Export restrictionNo
Drug status
Temporary cessation of marketing of the medicinal product.
Last drug update date:9. 7. 2026